NCT01148511 - "Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus Treat and Extend Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)" | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Age-related Macular Degeneration

Interventions

DRUG

Ranibizumab 0.5 mg

Ranibizumab was supplied as a sterile solution in sealed glass vials.

Trial Locations (8)

Novartis Investigative Site, Adana

Novartis Investigational Site, Ankara

Novartis Investigative Site, Ankara

Novartis Investigative Site, Bursa

Novartis Investigative Site, Eskişehir

Novartis Investigative Site, Istanbul

Novartis Investigative Site, Izmir

Novartis Investigative Site, Konya